Topics in pediatric leukemia - Acute myeloid leukemia

MedGenMed Medscape General Medicine

Volumn 7, Issue 1, 2005, Pages

  Cheng, Jerry ^a   Sakamoto, Kathleen M ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IMATINIB; MITOXANTRONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOIC ACID; TIOGUANINE; VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKAPHERESIS; PATHOPHYSIOLOGY;

EID: 25144462569     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Nathan D, Ginsburg D, Orkin SH, Look AT. In: Nathan D, ed. Nathan and Oski's Hematology of Infancy and Childhood. 6th ed. Philadelphia, Pa: WB Saunders Company; 2003:1168-1169.
2. Bhatia S, Neglia JP. Epidemiology of childhood acute myelogenous leukemia. J Pediatr Hematol Oncol. 1995;17:94-100.
3. Smith MA, Ries LG. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute; 1999:17-34.
4. Guidelines for the pediatric cancer center and role of such centers in diagnosis and treatment. American Academy of Pediatrics Section Statement Section on Hematology/Oncology. Pediatrics. 1997;99:139-141.
5. Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. Cancer Cell. 2002;2:437-445.
6. Pui CH, Relling MV, Rivera GK. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 1995;9:1990-1996.
7. Ravindranath YE, Abella J, Krischer P. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992;80:2210-2214.
8. Gamis AS, Woods WG, Alonzo TA. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003;21:3385-3387.
9. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9:139-149.
10. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14:43-47.
11. Dash A, Gilliland DG. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:49-64.
12. Raimondi SC, Chang MN, Ravindranath Y. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group Study - POG 8821. Blood. 1999;94:3707-3716.
13. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
14. Martinez-Climent JA. Molecular cytogenetics of childhood hematological malignancies. Leukemia. 1997;11:1999-2021.
15. Baumann I, Nenninger R, Harms H. Image analysis detects lineage-specific morphologic markers in leukemic blast cells. Am J Clin Pathol. 1996;105:23-30.
16. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
17. Schwartz MW, Bell LM, Bingham PM, et al. The 5 Minute Pediatric Consult. 1st ed. Schwartz MW, ed. Philadelphia, Pa: Williams & Wilkins; 1997:893.
18. Menell JS, Cesarman JM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340:994-1004.
19. Stevens R, Hann I, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol. 1998;101:130-140.
20. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
21. Feig SA, Lampkin B, Nesbit ME, et al. Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Children's Cancer Group. Bone Marrow Transplant. 1993;12:65-71.
22. Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 4th ed. Pizzo PA, Poplack DG, eds. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:1691.
23. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97:56-62.
24. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101:3868-3871.
25. Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003;102:1474-1479.
26. Grier HE, Gelber RD, Camitta BM, et al. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol. 1987;5:1026-1032.
27. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23:4255-4262.
28. Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302-2309.
29. Parsons SK, Gelber S, Cole BF, et al. Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: a Q-TWiST analysis of the Pediatric Oncology Group Study 8821. J Clin Oncol. 1999;17:2144-2152.